QUICK REF — Evidence 5/5 (rickets/falls in deficient) to 1/5 (weight loss, cancer incidence) | Dose 1,000–2,000 IU/day with fat | Target 25(OH)D 30–50 ng/mL (older Endocrine Society) or RDA-only (2024 Endocrine Society) | Monitor: 25(OH)D baseline, 3mo, then annually | Key interactions: thiazides → hypercalcemia; corticosteroids + anticonvulsants ↑ catabolism | Co-factor mandatory at >2,000 IU: Vitamin K2 (MK-7) 100–200 mcg/d + Magnesium 400 mg/d
STATUS — Best-characterized deficiency-correction agent in medicine. 2024 Endocrine Society guideline dropped universal screening + supplementation for healthy adults 19–74. Benefits concentrate in deficient populations, elderly ≥75, pregnancy, prediabetes. Null for most extraskeletal outcomes in replete adults.
Clinical Summary
Vitamin D3 is a fat-soluble secosteroid hormone synthesized in skin from 7-dehydrocholesterol via UVB, then 25-hydroxylated in liver (→ 25-OHD) and 1α-hydroxylated in kidney (→ 1,25-(OH)₂D, the active form). The active metabolite binds the Vitamin D Receptor (VDR), a nuclear receptor expressed in virtually every tissue — which is why D3 touches calcium/bone, innate immunity, adaptive immunity, RAAS, and epigenetic aging.
Who benefits most: People with 25(OH)D <20 ng/mL, elderly >75, dark-skinned individuals at northern latitudes, institutionalized persons, those with malabsorption (celiac, Crohn's, bariatric), pregnant women, prediabetic adults with severe deficiency. Benefits in replete healthy adults are minimal to null.
The evidence arc, 2017 → 2026: Bone/falls in deficient elderly (unequivocal), pregnancy outcomes (solid), and autoimmune disease incidence (VITAL) held up. Respiratory infection prevention has attenuated (Jolliffe 2025 lost statistical significance with 6 new RCTs). Cancer incidence, CVD events, T2D prevention in non-deficient populations, cognitive decline, depression, PCOS-IVF live birth, and COVID-19 outcomes have all collapsed under large RCT scrutiny (VITAL, D-Health, D2d, DO-HEALTH, DepFuD, Mongolia COVID, Finnish dementia, BMJ PCOS-IVF). One new signal emerged: RCT-level telomere preservation (VITAL 2025 + India replication 2025) — the first hard aging biomarker evidence.
Threshold rule: Nearly all clinical benefit concentrates at baseline 25(OH)D <20 ng/mL. Raising already-replete levels (>30 ng/mL) to higher numbers shows minimal additional benefit for most outcomes (PMID 30841596).
Indications & Evidence
| Indication | Evidence | Type | BH | Safety | Effect Size | Population | Dose | Duration | Key PMID |
|---|---|---|---|---|---|---|---|---|---|
| Rickets / osteomalacia | 5/5 | DC | 9/9 | -- | ~100% prevention + full reversal | Infants, children, adults with deficiency | 400 IU/d prevent; 2,000–4,000 IU/d treat | 2–6 mo | 34969941 |
| Hip fracture prevention (with Ca) | 5/5 | PC | 8/9 | MON | 16% hip-fracture reduction (D+Ca) | Elderly >65, deficient, institutionalized | 800–2,000 IU/d + 1,000 mg Ca | 12–36 mo | 24729336, 22762317, 29279934 |
| Falls prevention (elderly, deficient) | 4/5 | PC | 7/9 | MON | 20–30% fall reduction (community-dwelling) | Elderly >65 w/ baseline 25(OH)D <20 ng/mL | 800–1,000 IU/d daily | 3–6 mo | 15886381, 40832852 |
| Preeclampsia prevention | 4/5 | PC | 7/9 | -- | 15–40% risk reduction | Pregnant women, deficient | 1,000–4,000 IU/d | Throughout pregnancy | 29217750, 39716171, 39077939 |
| Maternal D → offspring bone/child health | 4/5 | PC | 7/9 | -- | BMD + microarchitecture at age 6 | Maternal D3 supplementation | 1,000 IU/d from 14 wk | Through term | 41802552, 39834161 |
| Autoimmune disease incidence (VITAL) | 4/5 | PC | 6/9 | -- | HR 0.78; persists 2 yr post-trial | General pop, mostly ≥50 | 2,000 IU/d (± omega-3) | 5.3 yr + 2 yr follow-up | 34756744, 38272846 |
| All-cause mortality | 3/5 | PC | 6/9 | -- | RR 0.96–0.98 (cancer-mortality driven) | Pooled RCT populations | 1,000–4,000 IU/d daily | ≥3 yr | 37004841, 41719624 |
| Cancer mortality (not incidence) | 3/5 | UCC | 5/9 | -- | HR 0.88 daily dosing; bolus null | Pooled (IPD meta) | Daily only, 2,000–4,000 IU/d | ≥4 yr | 37004841, 30415629 |
| Telomere preservation | 3/5 | BC | 5/9 | -- | 140 bp reduced attrition / 4 yr | VITAL (US) + India replication | 2,000 IU/d | 4 yr | 40409468, 40862088 |
| Epigenetic / biological aging (DO-HEALTH) | 3/5 | BC | 5/9 | -- | ~2.9 mo/yr DNA-methylation age reduction (with exercise) | Healthy ≥70 | 2,000 IU/d + omega-3 + exercise | 3 yr | 39900648 |
| Muscle strength / sarcopenia (deficient) | 3/5 | PC | 6/9 | MON | 10–20% strength gain in deficient; null alone in elderly | Elderly/athletes with deficiency | 1,000–2,000 IU/d + protein + exercise | 3–6 mo | 41319491, 41422832, 39565152 |
| Blood pressure (in deficient hypertensives) | 3/5 | SE | 5/9 | -- | 2–6 mmHg SBP reduction | Hypertensive + deficient | 2,000–4,000 IU/d | 3–6 mo | 37895163 |
| MS relapse (deficient MS patients) | 3/5 | UCC | 5/9 | -- | Reduced relapse rate in low-25(OH)D MS | Established MS + deficiency | 4,000–10,000 IU/d | ≥12 mo | 41983136, 40554210 |
| Autoimmune disease activity (RA, SLE, IBD, Hashimoto's) | 3/5 | UCC | 4/9 | -- | 10–30% reduction in inflammatory markers | Established autoimmune | 2,000–4,000 IU/d | Ongoing | 31533487, 41952022 |
| T2D progression in prediabetic + deficient | 3/5 | UCC | 5/9 | -- | 10% progression reduction; 76% in ≥100 nmol/L subgroup | Prediabetic + baseline <20 ng/mL | 3,500–4,000 IU/d | 2.5 yr | 31173679, 37001590, 41707752 |
| Respiratory infection prevention | 3/5 | UCC | 5/9 | -- | OR ~0.92 overall; stronger in deficient, daily dosing, ≤50 µg/d | Children + deficient | 400–1,200 IU/d daily | 3–12 mo | 28202713, 39993397 |
| Psoriasis (adjunct) | 3/5 | PC | 5/9 | -- | Modestly effective as adjunct in network meta | Plaque psoriasis | Topical (calcipotriene) or oral 2,000–5,000 IU/d | 3–6 mo | 41459063 |
| Sleep quality | 2/5 | BC | 3/9 | -- | Modest improvement (PSQI) | Deficient/mixed | 2,000–4,000 IU/d | 8–12 wk | 41470897 |
| Depression (in deficiency) | 2/5 | UCC | 3/9 | -- | Inconsistent; two large 2026 RCTs negative | Deficient + clinically depressed | 2,000–4,000 IU/d | 8–24 wk | 41933624, 41506003, 41923913, 36462182 |
| Cancer incidence | 2/5 | NE | 2/9 | -- | Null in VITAL, D-Health | General pop, mostly replete | 2,000 IU/d or 60k/mo | 5 yr | 30415629, 40096917 |
| CVD events (MI/stroke) | 2/5 | NE | 2/9 | -- | Null in VITAL, D-Health | General pop | 2,000 IU/d or bolus | 5 yr | 30415628, 41599971 |
| Cognitive decline / dementia | 2/5 | NE | 2/9 | -- | Null in Finnish Vitamin D Trial + network meta | Elderly | 1,600–3,200 IU/d | 5 yr | 40243375, 41764841 |
| COVID-19 severity / Long COVID | 2/5 | NE | 2/9 | -- | Negative large Mongolia RCT 2026 | Community, adults + children | Standard dosing | 4–24 wk | 41826107, 41156485 |
| PCOS / IVF live birth | 1/5 | NE | 2/9 | -- | Negative BMJ multicentre RCT 2026 | PCOS + IVF | Pre-IVF D3 | 8–12 wk pre | 41702641 |
| Prostate cancer progression | 1/5 | NE | 2/9 | -- | Negative ProsD Phase II 2026 | Prostate cancer + deficiency | High-dose D3 | 12 mo | 41423505 |
| Cardiometabolic disease prevention | 1/5 | NE | 2/9 | -- | D-Health negative 5 yr | Adults 60–84 | 60,000 IU/mo bolus | 5 yr | 41599971 |
| Weight loss | 1/5 | NE | 1/9 | -- | None | — | — | — | — |
| Testosterone increase | 1/5 | NE | 2/9 | -- | Clinically negligible | Healthy men | 3,000–5,000 IU/d | 12 wk | — |
| ADHD | 1/5 | FA | 1/9 | -- | None | Pediatric | — | — | — |
Type codes: DC = Direct Causal | PC = Probable Causal | UCC = Unresolved Causal Chain | BC = Biomarker Change | SE = Surrogate Endpoint | ME = Mechanism Extrapolation | AHE = Anecdotal | OA = Observational Association | NE = No Effect | FA = False Assumption
BH = Bradford Hill score /9 (9 criteria: strength, consistency, specificity, temporality, dose-response, plausibility, coherence, experiment, analogy)
Safety codes: -- = no FAERS signal for this pathway | MON = mild/manageable AEs | WARN = serious FAERS signal | AVOID = contraindicated for this use
Critical nuance #1 — D3 alone vs. D3+Ca: Bolland 2018 meta-analysis (PMID 30293909, N=53,537 unselected adults) found no benefit for fractures/falls/BMD from D3 alone. Fracture benefit requires D3 + calcium + elderly + deficiency.
Critical nuance #2 — daily vs. bolus: Intermittent high-dose regimens (500,000 IU/year, 60,000 IU/month) consistently underperform daily dosing — for ARI (PMID 39993397), cancer mortality (PMID 37004841), fractures (PMID 38615341), and fall prevention. Daily dosing wins across endpoints. Bolus may actually increase fall risk early post-dose.
Critical nuance #3 — 2024 Endocrine Society paradigm shift (PMID 38828931): Dropped universal 30 ng/mL target, dropped routine 25(OH)D screening for healthy adults <75, recommends empiric low-dose only for children 1–18, adults ≥75, pregnancy, and high-risk prediabetes. This is a genuine evidence-driven reversal — it reflects accumulated null RCTs in non-deficient populations. Pludowski/Grant rebuttal (PMID 39861407) and Holick critique (PMID 39486479) argue it underweights autoimmune, cancer mortality, and respiratory data. Mayo Clin Proc (PMID 39938796) questions if it went too far.
Prescribing
Dosing
| Population | Dose | Timing | Notes |
|---|---|---|---|
| Healthy adults 19–74 (2024 Endocrine Society) | 600–800 IU/d (RDA) | With fat-containing meal | No empiric supplementation recommended; routine 25(OH)D screening not recommended |
| Healthy adults 19–74 (clinical-practice heuristic) | 1,000–2,000 IU/d | With breakfast + fat | Reasonable hedge given deficiency prevalence; diverges from 2024 guideline |
| Adults ≥75 | 800–2,000 IU/d (empiric) | With breakfast | 2024 Endocrine Society explicitly endorses empiric supplementation |
| Deficiency correction (25(OH)D <20 ng/mL) | 50,000 IU/week × 8 wk | Then 1,000–2,000 IU/d maintenance | Recheck 25(OH)D at 8 wk |
| Pregnancy | 1,000–4,000 IU/d | Any meal with fat | Safe per ACOG; 2024 Endocrine Society endorses empiric |
| Pediatric (>1 yr) | 600–1,000 IU/d | With food | 400 IU/d for breastfed infants from birth (AAP) |
| High-risk prediabetic (deficient) | ~3,500 IU/d | With meal | 2024 Endocrine Society endorses; based on D2d trial |
| Malabsorption (celiac, Crohn's, bariatric) | 3–5× standard, or calcidiol | With fat | Consider liposomal or calcidiol — 3× more potent per µg (PMID 39385006) |
| Renal eGFR <30 | Calcitriol or calcidiol under nephrology | — | Standard D3 won't convert adequately |
| On corticosteroids | +1,000–2,000 IU/d | With food | ↑ D3 catabolism + impaired Ca absorption |
| On anticonvulsants | 4,000–6,000 IU/d | With food | CYP inducers ↑ D3 catabolism; monitor q3mo |
| Obese (BMI ≥30) | 1.5–2× standard dose | With meal | Volumetric dilution in adipose; D3 > D2 in high-BMI (PMID 37865222) |
Upper Limit: EFSA 2023 set UL at 100 µg/d (4,000 IU) for adults, pregnancy, and lactation (PMID 37560437). IOM/NAM UL also 4,000 IU/d. Doses above UL should be time-limited, lab-monitored, or justified by specific indication (malabsorption, Coimbra protocol).
Formulations
| Form | Bioavailability | When to Use | Cost |
|---|---|---|---|
| D3 cholecalciferol (capsule/tablet) | 55–99% (with fat) | First line for everyone | $ ($5–15/mo) |
| D3 liquid drops | 80–95% | Flexible dosing, children, elderly | $$ ($10–20/mo) |
| Calcifediol (25-OHD3) | ~90% (fat-independent); ~3× potency per µg | Liver disease, malabsorption, bariatric, obesity | $$$ ($50–100+/mo) |
| Liposomal D3 | 80–95% | Malabsorption, poor response to standard | $$$$ ($20–40/mo) |
| D2 ergocalciferol | 30–70% | Only if strict vegan; D3 raises 25(OH)D 87% more (PMID 22552031, 37865222) | $ |
| IM cholecalciferol (300k–600k IU) | High peak | Non-adherent patients; bolus risks as above | N/A |
D3 vs D2 settled: D3 is clinically superior for raising 25(OH)D (PMID 37865222). No reason to use D2 unless strict vegan and cannot source lichen-derived D3.
Daily vs. Bolus
- Daily dosing wins for ARI (PMID 39993397), cancer mortality (PMID 37004841), fracture prevention, fall prevention
- Bolus equivalent only for raising total 25(OH)D levels
- Bolus potentially worse for fall risk (may ↑ early post-dose), duration of innate immune activation
Condition-Specific Protocols
1. Correcting Deficiency (25(OH)D <20 ng/mL) — 5/5 first-line use
Load phase: 50,000 IU/week × 8 weeks (or 5,000 IU/day × 8 weeks). Retest at 8 weeks. Maintenance: 1,000–2,000 IU/day once 25(OH)D ≥30 ng/mL. Cofactors: Magnesium 300–400 mg/d (required for both hydroxylation steps — deficiency blunts D3 response), Vitamin K2 MK-7 100 mcg/d (if dosing ≥2,000 IU/d ongoing). Monitoring: 25(OH)D + serum calcium at baseline and 8 weeks.
2. Elderly Fall & Fracture Prevention — 5/5
Target population: Community-dwelling or institutionalized ≥65, baseline 25(OH)D <20 ng/mL. Dose: 800–2,000 IU D3/d + 1,000–1,200 mg calcium/d + Vitamin K2 MK-7 100–200 mcg/d. Crucial caveat: Cochrane 2025 (PMID 40832852) in care-facility residents with low D: D3 probably reduces rate of falls (RaR 0.63, 95% CI 0.46–0.86; 5 trials, 4,603 participants; moderate certainty) but probably makes little or no difference to the risk of falling (RR 0.99, 95% CI 0.90–1.08; 6 trials, 5,186 participants). In other words, it reduces how often each person falls, but not whether they fall at all. Do not use bolus dosing for fall prevention (Tao 2024, PMID 38615341).
3. Pregnancy — 4/5
Target population: All pregnant women, especially with baseline 25(OH)D <30 ng/mL. Dose: 1,000–4,000 IU/d from first trimester through lactation. Outcomes: reduced preeclampsia, GDM, SGA, neonatal mortality (Cochrane 2024 PMID 39077939; meta 39716171, 41737411). Child benefits at age 6: improved bone microarchitecture (MAVIDOS PMID 41802552), reduced atopic dermatitis in some subgroups.
4. High-Risk Prediabetic + Deficient — 3/5
Target population: Prediabetes + baseline 25(OH)D <20 ng/mL. Dose: 3,500–4,000 IU/d. Evidence base: D2d trial primary analysis null overall (PMID 31132708), but subgroup achieving ≥100 nmol/L showed 76% risk reduction in Black/obese prediabetics (PMID 37001590). Amrein 2026 mini-review (PMID 41707752) consolidates. The only non-bone indication the 2024 Endocrine Society guideline explicitly endorses for adults 19–74.
5. Autoimmune Disease Incidence Reduction — 4/5
Target population: General pop ≥50; not yet diagnosed with autoimmune disease. Dose: 2,000 IU/d (VITAL regimen). Evidence: VITAL autoimmune arm HR 0.78 for new autoimmune disease (PMID 34756744). Effect persisted 2 years post-trial (PMID 38272846). Not a treatment for established autoimmune disease — activity reduction is modest (10–30% inflammatory markers, not remission).
Safety
Interactions
| Interactant | Effect | Management |
|---|---|---|
| Thiazide diuretics | ↓ urinary Ca → hypercalcemia risk | Monitor serum Ca q3mo; cap D3 at 2,000 IU/d |
| Digoxin / cardiac glycosides | Hypercalcemia → arrhythmia risk | Monitor Ca + ECG; cap D3 at 2,000 IU/d |
| Corticosteroids | ↑ D3 catabolism; ↓ Ca absorption | +1,000–2,000 IU D3; add Ca |
| Anticonvulsants (phenytoin, phenobarbital, carbamazepine) | ↑ CYP catabolism → osteomalacia risk | 4,000–6,000 IU/d; monitor 25(OH)D q3mo |
| Rifampin | ↑ CYP metabolism | 4,000–6,000 IU/d; monthly monitoring |
| Orlistat | ↓ fat-soluble vitamin absorption | Separate by 2 h; consider higher dose |
| Cholestyramine / bile-acid sequestrants | ↓ absorption 30–50% | Space 4–6 h; increase dose |
| Calcipotriene (topical D3 analog for psoriasis) | Additive vitamin D effect | Monitor Ca; may reduce oral D3 |
| Calcium-containing antacids | Additive hypercalcemia risk at high doses | Cap total Ca at 1,200 mg/d |
| Aluminum-containing antacids | D3 ↑ aluminum absorption | Avoid in CKD |
Contraindications
Absolute:
- Hypercalcemia (any cause) — correct calcium first
- Severe hypercalciuria — stone + renal damage risk
- Williams syndrome — genetic infantile hypercalcemia
- Known vitamin D hypersensitivity / active vitamin D toxicity
Relative:
- Granulomatous disease (sarcoidosis, TB, berylliosis) — extrarenal 1α-hydroxylase causes uncontrolled calcitriol production; monitor Ca closely, cap dose
- History of calcium-containing kidney stones — use ≤2,000 IU/d with hydration
- Severe renal impairment (eGFR <30) — use calcidiol or calcitriol under nephrology
- Primary hyperparathyroidism — treat PTH first
- Paraneoplastic 1,25-OH-D hypercalcemia (e.g., dedifferentiated liposarcoma — PMID 41980790) — do not supplement
Adverse Effects
At physiologic doses (≤4,000 IU/day): essentially none. Vitamin D has a remarkably wide therapeutic index.
- Hypercalcemia: <1% at ≤4,000 IU/d; 2–5% at chronic >10,000 IU/d. Requires months of excess at standard oral doses.
- Toxicity threshold: 25(OH)D >150 ng/mL (requires >10,000 IU/d for months OR single >300,000 IU IM dose)
- Hypercalciuria: 5–10% at >4,000 IU/d; kidney stone risk
- Toxicity case literature: Most documented cases involved >40,000 IU/d for months (PMID 30042329), dispensing errors, or compounding errors. BMJ 2022 case report: 150,000 IU/d caused hospitalization with polyuria, vomiting, weight loss, tinnitus, AKI.
- Rodenticide cholecalciferol toxicity (PMID 41992351): osteomyelitis after ingestion — rodenticide doses are >100× human therapeutic doses and are not relevant to oral supplementation.
- No withdrawal effects: Can stop abruptly; 25(OH)D declines slowly (half-life ~15 days).
- Paradoxical reactions (community-reported, weak evidence): anxiety/jitters, insomnia (especially with evening dosing), palpitations. Commonly attributed by folk medicine to magnesium depletion; mechanism plausible but not rigorously tested.
FAERS Signal Table (OpenFDA, cholecalciferol, retrieved 2026-04-17, N=74,217 total reports)
| Reaction | Count | Linked indication | Severity | Interpretation |
|---|---|---|---|---|
| Hypercalcaemia | ~384 | Toxicity | Serious | True D3 signal; dose + duration dependent |
| Nephrolithiasis | ~422 | Hypercalciuria complication | Moderate–Serious | Dose + duration dependent; preventable with hydration + Ca monitoring |
| Fatigue | 7,734 | Non-specific | Mixed | Dominated by multivitamin / Fosamax+D co-reporting |
| Off-label use | 7,559 | Regulatory | N/A | Regulatory flag, not adverse event |
| Diarrhoea | 6,416 | GI | Non-serious | Likely multivitamin co-reporting |
| Nausea | 6,085 | GI / hypercalcemia | Mixed | Partially D3-signal (hypercalcemia cluster: nausea 105 co-reports within hypercalcemia reports) |
| Dyspnoea | 5,449 | Cardiopulmonary | Serious | Likely combination-product + elderly polypharmacy |
| Headache | 5,412 | Non-specific | Non-serious | Dominated by multivitamin noise |
FAERS interpretation (per vault pharma-skepticism protocol): The 74,217-report headline is misleading. True D3-attributable signals are hypercalcemia (384) and nephrolithiasis (422) — biologically plausible, dose/duration-dependent, preventable with monitoring. The top ten "adverse reactions" are dominated by (1) Fosamax Plus D (alendronate combination) reporting, (2) Infuvite Pediatric parenteral multivitamin, and (3) elderly polypharmacy background. Pure oral D3 supplement signal is minimal. Death outcomes (1,912 reports) cluster in multimorbid hospitalized patients on parenteral or multivitamin cholecalciferol, not on oral D3 toxicity.
Monitoring
| Test | When | Target |
|---|---|---|
| 25(OH)D | Baseline (if high-risk), 3 mo after dose change, then annually | 30–50 ng/mL (older Endocrine Society); 20–40 ng/mL (IOM); no target (2024 Endocrine Society) |
| Serum calcium | Baseline; q3 mo if >4,000 IU/d or on thiazides/digoxin | <10.5 mg/dL |
| PTH | Baseline if bone disease / CKD suspected | Normalize |
| eGFR / creatinine | Baseline in elderly, CKD, on thiazides | Monitor annually |
| 24-hour urinary calcium | If on >4,000 IU/d chronically or stone history | <250 mg/d (F), <300 mg/d (M) |
Red flags: 25(OH)D >100 ng/mL → reduce dose. 25(OH)D >150 ng/mL → stop, monitor Ca, evaluate symptoms. Serum Ca >10.5 → investigate.
Special Populations
- Pregnancy/Lactation: Safe at 1,000–4,000 IU/d (ACOG, Cochrane 2024). Do not exceed UL without specialist oversight. Maternal D status sets infant D status for first 4–6 mo; breastfed infants should receive 400 IU/d independent (AAP).
- Infants: 400 IU/d from first week of life if breastfed. Rickets prevention non-negotiable.
- Elderly ≥75: Empiric supplementation recommended; lower muscle synthesis, lower cutaneous production, higher fall risk.
- Obese (BMI ≥30): Need ~1.5–2× standard dose due to volumetric dilution in adipose.
- Dark-skinned + northern latitudes: Higher risk of deficiency year-round; higher doses often needed.
Synergies & Stacking
| Co-nutrient | Why | Dose | Evidence |
|---|---|---|---|
| Calcium | D3 ↑ intestinal Ca absorption 10–15% → 30–40%; combined = fracture prevention; without Ca, D3 has no fracture effect | 1,000–1,200 mg/d total (diet + supp) | 5/5 |
| Magnesium | Required cofactor for 25-hydroxylase and 1α-hydroxylase; Mg deficiency blunts D3 response and may drive paradoxical anxiety at high doses | 300–400 mg/d | 4/5 |
| Vitamin K2 (MK-7) | Activates D3-dependent proteins (osteocalcin, MGP); directs Ca to bone vs. arteries; practically mandatory at D3 >2,000 IU/d ongoing | 100–200 mcg/d MK-7 | 4/5 |
| Boron | Inhibits 24-hydroxylase → extends D3 half-life; may help non-responders | 3–6 mg/d | 3/5 |
| Zinc | May enhance VDR function; frequently co-deficient | 15–30 mg/d | 3/5 |
| Vitamin A | VDR-RXR heterodimer requires balanced retinoid; excess A antagonizes D3 | Diet-based; supplementation usually not needed | 3/5 |
| Omega-3 | Anti-inflammatory synergy (tested together in VITAL, DO-HEALTH); DO-HEALTH DNA-methylation benefit required both | 1–2 g/d EPA+DHA | 3/5 |
| Protein + resistance exercise | Required for sarcopenia/muscle benefit — D3 alone is null (PMID 41319491, 41422832, 39565152) | 1.2–1.6 g/kg protein + 2–3×/wk resistance | 4/5 |
Key stacking rule: Vitamin K2 MK-7 100–200 mcg/d is essentially mandatory once D3 dose exceeds 2,000 IU/d and continues for months. Without K2, D3-driven increased calcium absorption favors soft-tissue calcification over bone mineralization. Magnesium is the most commonly neglected cofactor — and the one most associated with "D3 didn't work for me" and paradoxical anxiety/insomnia complaints.
Individual Response Modifiers
Sex-Specific Considerations
| Modifier | Direction | Evidence | Action |
|---|---|---|---|
| Pregnancy / lactation | ↑ requirement | Strong — multiple RCTs + Cochrane 2024 | 1,000–4,000 IU/d from first trimester; continue during lactation |
| Menopause (postmenopausal) | ↑ deficiency prevalence, ↑ fracture relevance | Strong | Baseline 25(OH)D; target 30–40 ng/mL with K2 + Ca |
| Female body fat % higher at same BMI | Slightly ↑ dose requirement | Moderate — volumetric dilution | Consider 1.25–1.5× male dose at equivalent BMI if obese |
| Maternal D → offspring bone | Strong — MAVIDOS (PMID 41802552, 39834161) | MAVIDOS | Maternal supplementation has lifelong offspring effects |
| Male testosterone — claimed benefit | Clinically negligible | Moderate — small RCTs | Do NOT supplement for testosterone purposes |
| Study populations | Most large trials (VITAL, DO-HEALTH) slight female majority; D2d 55% male | Per-trial demographics | Effect estimates are generalizable; no known sex interaction for most outcomes |
Genetic Modifiers
| Variant / gene | Phenotype | Evidence | Action |
|---|---|---|---|
| VDR FokI (rs2228570) | Ff/ff: altered VDR transcription; associations with Graves', lupus, CRC prognosis | Moderate — consistent but unclear clinical utility | Not actionable as single variant; consider if poor response |
| VDR BsmI (rs1544410) | Associations with BMD, autoimmunity, T2D | Moderate | Not routinely tested |
| VDR TaqI, ApaI | Various disease associations | Weak–moderate | Not routinely actionable |
| CYP2R1 (25-hydroxylase) | Loss-of-function → low 25(OH)D despite adequate D3 intake; "non-responder" phenotype | Strong — mechanistic | If 25(OH)D fails to rise on adequate dose, consider calcifediol (bypasses CYP2R1) |
| CYP24A1 (24-hydroxylase — catabolism) | LoF → idiopathic infantile hypercalcemia; GoF → D3 resistance | Strong in rare disease | Pediatric hypercalcemia workup; screen before high-dose D3 if family history |
| GC / DBP (vitamin D binding protein) | Variants alter 25(OH)D bioavailability; may make total 25(OH)D misleading | Moderate | Consider free 25(OH)D in unexplained response gap |
| VDBP 2026 mechanism (PMID 41963327) | DBP causes muscle atrophy independent of D status | Emerging | Research-only; not yet actionable |
Evidence basis: VDR polymorphisms have consistent associations with autoimmune risk (Graves', SLE, MS) and cancer prognosis but are not routinely tested and do not currently drive dosing decisions. CYP2R1/CYP24A1 loss-of-function are rare but explain true "vitamin D non-responders" — the fix is calcifediol, which bypasses the first hydroxylation step.
Community & Anecdotal Evidence
Disclaimer: Everything in this section is anecdotal, community-sourced, and NOT clinical evidence. Folk sentiment skews positive because null experiences rarely get posted. Use to generate hypotheses, not to override RCTs.
Source communities + dominant sentiment
| Community | Sentiment | Approx N | Dominant claim |
|---|---|---|---|
| r/Supplements, r/Nootropics | Strongly positive | Thousands of threads | Energy + winter mood |
| r/VitaminD | Mixed-positive | Hundreds | More toxicity caution |
| r/Psoriasis, r/MultipleSclerosis | Strongly positive (high-dose) | ~100s | Dramatic clearance / relapse reduction |
| r/Hashimotos, autoimmune | Mixed-positive | ~100s | Antibody reductions at 2,000–4,000 IU |
| Phoenix Rising (ME/CFS) | Mixed / unusually negative | Dozens of threads | Paradoxical fatigue worsening subset |
| Psoriasis Association UK, Inspire | Strongly positive | Dozens | 40k–60k IU clearance testimonials |
| Coimbra Protocol community | Extremely positive (in-group) | Thousands globally | 40k–300k IU/d for autoimmune |
| Mercola audience | Positive but trust-damaged | Large | FDA warning letters 2021 for false COVID claims |
| Berg / Huberman / Rhonda Patrick | Positive | Mass audience | 5k–10k IU/d normalized |
| Japanese/Korean forums | Deficiency-focused, pragmatic | N/A | Food fortification focus, less megadose culture |
Most-reported subjective effects (ranked)
- Energy / fatigue reduction (overwhelming #1, especially previously-deficient)
- Mood / winter depression / SAD relief (2-week onset typical)
- Fewer colds / respiratory infections (matches 2017 Martineau narrative)
- Psoriasis skin clearance (dramatic at 30k–60k IU/d, clinical or community)
- Joint crepitus / cracking relief (returns off-dose)
- Sleep improvement (morning dosing) or disruption (evening dosing)
- Libido / ED (in previously-deficient men)
- Hair regrowth / reduced shedding (deficient subset)
Most-reported adverse / paradoxical effects
- Anxiety, jitters, panic — community attributes to Mg depletion
- Insomnia — common with evening dosing
- Hypercalcemia symptoms — at chronic >10k IU without monitoring
- Kidney stones — reported in Coimbra protocol users despite water protocol
- Palpitations — at high doses, community attributes to K2 absence
- Paradoxical fatigue worsening — notable ME/CFS subset
- Hair loss — small subset
Folk dosing vs. clinical dosing
| Tier | Dose | Culture |
|---|---|---|
| Medical conservative (RDA) | 400–1,000 IU | NIH; rare on supplement forums |
| Mainstream biohacker | 2,000–5,000 IU | Reddit; matches clinical upper range |
| Huberman / Rhonda Patrick | 5,000–10,000 IU | Popular; above clinical guidelines |
| Berg / Mercola | 10,000+ IU daily | Mass influencer; chronic use requires monitoring |
| High-dose fringe (VitaminDWiki, GrassrootsHealth) | 10,000–50,000 IU | Advocacy-driven |
| Coimbra protocol (MS/autoimmune) | 40,000–300,000 IU + Ca restriction + 2.5 L/d water | Supervised; survivorship bias; safety data PMC9033096 |
Red Flags & Skepticism Notes
- Mercola: FDA warning letters 2021 for false COVID-19 claims; CSPI pushed FTC enforcement; "liposomal D3" declared unapproved new drug.
- Berg: "10,000 IU is like 30 min summer sun" claim not peer-reviewed; sells branded D3.
- Coimbra protocol: Quasi-brand now; certified-practitioner network; survivorship-biased testimonial flywheel; real safety data exists but no independent RCT.
- GrassrootsHealth: Single-issue advocacy; reasonable data, but single-nutrient framing.
- VitaminDWiki: Aggregator, no editorial peer review.
- No MLM-native D3 brand dominant — unlike some supplements. Closest: practitioner-channel functional-medicine pricing.
- Supplement industry margin: D3 is one of the highest-margin supplements; "everyone is deficient" drives sales. ~42% of US adults ARE below 20 ng/mL, so narrative is half-true.
Folk vs. Clinical Reality Check
Folk consensus overlaps clinical evidence on: D3>D2, take with fat, pair with K2 at ≥2,000 IU, add magnesium, test baseline, morning dosing, energy + mood in deficient. Folk diverges from clinical evidence on: 10,000+ IU as default safe dose (no RCT support), Coimbra-level doses for autoimmune (uncontrolled), testosterone claims (clinically negligible), cancer prevention (null in VITAL + D-Health). The honest middle: 1,000–2,000 IU/d with K2 + Mg gets most of the benefit with minimal monitoring burden; higher doses are indicated only for correcting deficiency or specific conditions.
Deep Dive: Mechanisms & Research
Key Mechanisms (With Clinical Translation)
1. VDR-mediated gene regulation — 1,25-(OH)₂D binds VDR, a nuclear receptor that regulates ~3% of the human genome (~1,000 genes). Clinical translation: VDR polymorphisms explain part of individual response variation; explains breadth of non-skeletal effects.
2. Calcium-phosphate homeostasis — Increases intestinal Ca absorption from 10–15% to 30–40%. Suppresses PTH secretion. Enhances renal phosphate reabsorption. Clinical translation: D3 + calcium works for fractures, D3 alone does not — D3 enables calcium utilization but needs substrate.
3. Innate immune activation — Upregulates cathelicidin and β-defensins in respiratory epithelium and macrophages. Clinical translation: Respiratory infection reduction in deficient (PMID 28202713); attenuated but not eliminated in 2025 update (PMID 39993397).
4. Adaptive immune modulation — Promotes Tregs, suppresses Th1/Th17, modulates B-cell antibody production. Clinical translation: VITAL autoimmune HR 0.78 (PMID 34756744, 38272846); RA/SLE/IBD disease-activity reduction modest (10–30% markers, not remission).
5. RAAS suppression — Inhibits renin expression → ↓ angiotensin II + aldosterone; ↑ endothelial NO. Clinical translation: 2–6 mmHg SBP reduction in deficient hypertensives (PMID 37895163); meaningful adjunct, not medication replacement.
6. Telomere + epigenetic effects (2024–2025 frontier) — VITAL sub-study (PMID 40409468): 140 bp reduced telomere attrition over 4 yr. India replication in prediabetic women (PMID 40862088). DO-HEALTH DNA methylation clocks (PMID 39900648): D3 + omega-3 + exercise reduced epigenetic aging ~2.9 months/year. Clinical translation: First RCT-level support for "biological aging" claims; requires replication and outcome data.
7. Cancer-microbiome-immunity axis (2024 frontier) — Giampazolias Science 2024: D3 enhances checkpoint-inhibitor response via intestinal microbiome modulation. Clinical translation: Reframes cancer mortality signal — may potentiate immunotherapy rather than prevent incidence directly.
The Threshold Problem
Most important insight in D3 research: Nearly all clinical benefit concentrates in correcting deficiency (baseline 25(OH)D <20 ng/mL). Supplementing people already at 30+ ng/mL shows minimal additional benefit for most outcomes. This is why VITAL (N=25,871 mostly-replete Americans) and D-Health (N=21,315 Australians, mostly replete) found nothing for cancer incidence, CVD, or cognition, while studies in deficient populations show clear benefits.
The 2024 Endocrine Society paradigm shift (PMID 38828931) crystallized this insight into policy: don't screen universally, don't supplement universally, target high-risk subgroups.
Key Trials Backbone (2024–2026)
- VITAL (NCT01169259, N=25,871, 5.3 yr, D3 2,000 IU/d ± omega-3) — null for cancer incidence + CVD; positive for autoimmune incidence (HR 0.78) + cancer mortality + telomere preservation
- D-Health (NCT01538823, N=21,315, 5 yr, 60,000 IU/mo) — null for cancer incidence (PMID 40096917), cardiometabolic (PMID 41599971), all-cause mortality (PMID 35026158)
- DO-HEALTH (NCT01308762, N=2,157, 3 yr, 2×2×2 factorial D3 + omega-3 + exercise) — null for falls (PMID 35136915); positive DNA methylation aging only with exercise (PMID 39900648); null vertebral fractures (PMID 40492704)
- D2d (NCT01633177, N=2,423, 2.5 yr, 4,000 IU/d in prediabetes) — null overall (PMID 31132708); positive in ≥100 nmol/L subgroup (PMID 37001590)
- FIND (NCT01472445, N=2,495, 5 yr, 1,600/3,200 IU/d) — null for dementia (PMID 40243375); null for depression incidence (PMID 41506003)
- ViDA (NCT00736632, N=5,110, bolus D3) — null across outcomes
- DepFuD (2026, PMID 41933624) — null for 6-mo D3 in MDD
- Mongolia COVID RCT (2026, PMID 41826107) — null for COVID-19 severity and Long COVID
- BMJ PCOS-IVF (2026, PMID 41702641) — null for live birth
- ProsD Phase II (2026, PMID 41423505) — null for prostate cancer progression
Ataraxia Verdict (as of 2026-04-17)
Hype Check
Overblown claims:
- "Vitamin D prevents cancer" — VITAL + D-Health null for incidence. Possible modest mortality benefit with daily dosing, not bolus.
- "Higher is better" — No evidence 25(OH)D >50 ng/mL adds benefit for any outcome. Bolus mega-dosing may increase fall risk.
- "D3 treats depression" — Two negative large 2026 RCTs (DepFuD, Finnish FIND). Effect at best small and limited to deficient + clinically depressed.
- "D3 boosts testosterone" — Clinically negligible.
- "D3 prevents/treats COVID-19" — Null in large Mongolia 2026 RCT (PMID 41826107). Closes the COVID-era hype cycle.
- "D3 prevents cardiovascular disease" — Null VITAL, D-Health, D2d secondary.
- "D3 prevents dementia" — Null Finnish 5-yr RCT (PMID 40243375), null network meta (PMID 41764841).
- "Everyone needs 10,000 IU/d" — 1,000–1,500 IU/d reaches 30 ng/mL in 97.5% (PMID 28480855).
Legitimately supported:
- Rickets / osteomalacia prevention + treatment — 100% unambiguous
- Fracture prevention in elderly with calcium — 90,000+ participants across Cochrane reviews
- Fall prevention — 20–30% reduction in community-dwelling deficient elderly; rate of falls reduced (RaR 0.63) but not risk of falling in care-facility residents per PMID 40832852
- Preeclampsia + GDM + low birth weight reduction — Cochrane 2024 moderate certainty (PMID 39077939)
- Autoimmune disease incidence reduction — VITAL HR 0.78, persists 2 yr post-trial
- T2D prevention in prediabetic deficient — guideline-endorsed
- Telomere preservation (VITAL + India replication) — RCT-level biomarker evidence
- DNA-methylation aging reduction with D3 + exercise — DO-HEALTH 3-yr (PMID 39900648)
Evidence Classification (Mode 5)
Top 5–7 claims classified using causal taxonomy. Star ratings ≤ taxonomy ceiling enforced.
| Claim | Relationship | BH (/9) | Safety | Key Weakness |
|---|---|---|---|---|
| Rickets / osteomalacia prevention | DC | 9 | -- | None — textbook deficiency disease |
| Fracture reduction with Ca in elderly deficient | PC | 8 | MON | Null without calcium co-supplementation; null in unselected adults |
| Falls reduction in community-dwelling deficient elderly | PC | 7 | MON | Care facilities: reduces rate of falls (RaR 0.63) but not risk of falling (PMID 40832852); bolus may worsen |
| Preeclampsia / GDM prevention | PC | 7 | -- | Effect size varies; confounded with baseline D status |
| Autoimmune disease incidence reduction | PC | 6 | -- | Single large RCT (VITAL); absolute risk reduction modest |
| Telomere preservation | BC | 5 | -- | Biomarker, not outcome; needs replication beyond VITAL + India |
| Cancer mortality (not incidence) | UCC | 5 | -- | Subgroup finding; null in D-Health; mechanism via microbiome-immunity tentative |
| Respiratory infection prevention | UCC | 5 | -- | Jolliffe 2025 attenuated from 2017; effect small and heterogeneity-driven |
| Depression | UCC → NE | 3 | -- | Two 2026 RCTs negative; signal eroding |
| COVID-19, PCOS-IVF, prostate progression, cognition, CVD, cancer incidence | NE | 2 | -- | Multiple null large RCTs 2024–2026 |
Evidence Gaps
- Optimal 25(OH)D target for non-bone outcomes (20 vs 30 vs 40 vs 50 ng/mL) — societies disagree
- Long-term safety at sustained levels >80 ng/mL (Coimbra territory)
- Whether VDR / CYP2R1 genotyping should guide dosing in non-responders
- Whether bolus inferiority is dose-timing artifact or biology
- Individual dose-response variance (some need 5,000 IU/d to reach 30 ng/mL)
- Effect of deficiency correction in cancer patients (trials ongoing)
- Whether telomere + epigenetic aging signal translates to hard outcomes
- ME/CFS paradoxical-reaction subset — mechanism unknown
Bias Flags
- Observational-to-RCT gap: Observational studies consistently show strong D3-disease associations. RCTs largely fail to confirm. Classic confounding — healthy people are outside more, exercise more, eat better. Mendelian Randomization studies 2024–2025 further support reverse-causation interpretation: low D3 is often a marker of poor health, not a cause.
- Endocrine Society whiplash: Same society targeted 30 ng/mL in 2011, dropped all targets in 2024. This is evidence evolving, not a mistake — but undermines confidence in any single guideline.
- "Everyone is deficient" narrative: ~42% of US adults are below 20 ng/mL, so the story is half-true. But high-margin supplement economics amplify it beyond the evidence. 2024 Endocrine Society explicitly pushes back on over-supplementation in healthy 19–74.
- Respiratory infection downgrade: 2017 Martineau (42% reduction in deficient) was the strongest "universal D3" selling point. 2025 Jolliffe with 6 new RCTs including N=15,804 lost statistical significance overall. Earlier finding driven by smaller, lower-quality trials + heavily deficient populations.
- Subgroup survivorship: D2d positive finding required post-hoc subgroup (≥100 nmol/L, Black/obese). Subgroup findings without replication are fragile.
- Single-trial signals: Autoimmune (VITAL only), telomere (VITAL + India), cancer mortality (IPD meta of mixed quality) — all compelling but single-cohort-dominant.
Manipulation Flags
- Industry marketing: D3 is among the highest-margin supplements ($5–15/mo cost, often sold at $30+). "Clinical strength" labels (5,000 IU, 10,000 IU) used to justify higher prices without evidence those doses are better than 1,000–2,000 IU.
- Influencer economics: Berg (branded D3 sold via drberg.com), Mercola (FDA warning letters 2021 for false COVID claims; liposomal D3 declared unapproved new drug), Huberman (not paid directly for D3, but D3 central to his supplement narrative; drives partner brand sales). Rhonda Patrick (Thorne partnership).
- Cui bono — pro-supplementation: High-margin manufacturers, functional medicine practitioners billing for 25(OH)D tests, GrassrootsHealth advocacy, Coimbra Protocol practitioner-certification network. All benefit from the "higher is better" story.
- Cui bono — anti-supplementation: Competing pharma for osteoporosis drugs (bisphosphonates), some academic RCT-purists. No strong "anti-D3" commercial lobby — D3 is too cheap to threaten pharma materially.
- Supply chain economics: Raw D3 cholecalciferol powder costs <$0.01 per 1,000 IU dose at bulk manufacturer level. Retail markup 10–30× typical. 3rd-party tested brands (Thorne, Life Extension, Pure Encapsulations) cost more but variance in actual content vs. label is tight. Budget brands (NOW, Solgar, Carlson) are reliably potent.
- Researcher independence: Major D3 trialists (Manson/VITAL, Bischoff-Ferrari/DO-HEALTH, Holick, Pittas/D2d) have varying conflicts — some industry advisory, some pharma consulting. Endocrine Society 2024 guideline used GRADE methodology with declared conflicts. Holick (pro-high-dose) has significant industry ties; his critique of 2024 guideline (PMID 39486479) should be read in that context.
10-angle red team:
- Logical consistency — "D3 is essential but supplementing replete adults doesn't help" is internally consistent with hormone biology (feedback regulation).
- Evidence quality — Multiple large RCTs for most claims; highest-evidence-base supplement in existence.
- Cui bono — Massive pro-D3 commercial incentive; weak anti-D3 incentive. Adjust for industry optimism.
- Time horizon — D3 deficiency harms are slow (years) except rickets (months). Plan accordingly.
- Steelman anti-D3: "Most positive findings come from confounded observational data; RCTs in replete populations consistently null; the few RCT wins are subgroups that would benefit from a placebo." Reasonable, but ignores bone/fall/pregnancy/rickets unambiguous wins.
- Reversibility — D3 effects largely reversible (15-day 25(OH)D half-life); bone benefit takes months to lose.
- Second-order effects — K2 + Mg co-supplementation now normalized; Ca over-supplementation (without D3 + K2) drives the calcium paradox concern.
- Historical precedent — Rickets eliminated in 1930s via D3 fortification of milk. Public health win.
- Emotional loading — "Your depression is vitamin D deficiency" framing emotionally charged and mostly wrong per 2026 RCTs. "Vitamin D will cure your cancer" exploitative.
- Stranger test — Would recommend 1,000–2,000 IU/d + K2 + Mg to a stranger over 50 with no contraindications; would NOT recommend 10,000 IU/d without a 25(OH)D test.
Decision Support (Clarity Compass)
- Health utility score: 8/10 (compound-intrinsic). Rationale: highest evidence base of any supplement for correcting deficiency; broad downstream effects across bone, immune, autoimmune, pregnancy, biological aging. Downgraded from 9 because benefits in replete adults are null for most outcomes, and the 2024 guideline's "don't screen, don't supplement healthy 19–74" stance is evidence-consistent.
- Opportunity cost: Minimal. $5–15/month. One capsule with breakfast. Cognitive load negligible once stacked with K2 + Mg. Testing adds $25–75/yr if done annually.
- Hell Yes or No: Hell Yes for documented deficiency, elderly ≥75, pregnancy, prediabetic + deficient, elevated autoimmune risk. Conditional for healthy adults 19–74. No for testosterone, weight loss, cancer prevention, COVID-19, PCOS-IVF, dementia prevention.
- Regret minimization: In 5 years, would not regret 1,000–2,000 IU/d + K2 + Mg with occasional 25(OH)D check. Would regret chronic 10,000 IU/d without monitoring (stone risk). Would regret Coimbra-level doses without supervision. Would regret ignoring deficiency if >60 or institutionalized.
- Verdict: CONDITIONAL — ADD for specific conditions (deficiency <20 ng/mL, age ≥75, pregnancy, prediabetes + deficiency, elevated autoimmune risk). For healthy adults 19–74 without deficiency, either RDA-only (2024 Endocrine Society) or 1,000–2,000 IU/d + K2 + Mg as a low-cost hedge is reasonable. Do NOT ADD at doses >4,000 IU/d without lab monitoring. SKIP for testosterone, weight loss, cancer prevention, dementia prevention, COVID-19.
Bottom Line
Vitamin D3 is the most evidence-backed supplement in existence for specific populations — deficient individuals, elderly ≥75, pregnant women, prediabetic + deficient adults, and those at elevated autoimmune risk. It is also the most over-marketed supplement in existence for everyone else. The 2024 Endocrine Society paradigm shift is correct on the evidence: most extraskeletal benefits in replete adults are null. The 2024–2026 evidence stream has weakened the case for cancer prevention, CVD prevention, dementia prevention, depression treatment, COVID-19 effects, and PCOS-IVF outcomes, while strengthening the case for biological aging (telomere + epigenetic) and autoimmune incidence reduction. Take 1,000–2,000 IU/d with Vitamin K2 MK-7 + Magnesium + a fat-containing meal. Test 25(OH)D if you have risk factors (age, latitude, skin tone, malabsorption, pregnancy). Don't chase 25(OH)D above 50 ng/mL. Don't use bolus dosing. Don't take 10,000+ IU/d chronically without monitoring.
Practical Notes
- Always take with fat — absorption increases 32–50% with a fat-containing meal
- Daily > bolus — steadier 25(OH)D, better outcomes across endpoints
- Morning > evening — evening dosing sometimes disrupts sleep (community-reported)
- Brands (3rd-party tested): Thorne (D/K2 combo popular), Life Extension, Seeking Health, NOW Foods, Pure Encapsulations, Carlson
- Avoid: Mercola-branded (FDA warning history), any "proprietary blend" without per-nutrient disclosure
- Storage: Room temperature, away from light. D3 stable; liquid drops last to expiration date once opened
- Palatability: Capsules odorless; liquid drops often olive-oil or MCT-based, mildly oily taste
- Cost: $5–15/month for standard D3 cholecalciferol 1,000–5,000 IU; calcifediol premium $50–100+/mo
- Exercise timing: D3 benefits potentiate with exercise (DO-HEALTH methylation required exercise; sarcopenia benefit requires resistance training + protein); no need to time around workouts
- Reference ranges (25(OH)D): <20 ng/mL = deficient; 20–29 = insufficient (2011 Endocrine Society); 30–50 = sufficient (2011 ES); >100 = reduce dose; >150 = toxicity threshold. 2024 Endocrine Society dropped these targets; IOM uses ≥20 ng/mL as sufficiency.
- Liquid drops allow flexible dosing (great for pediatric or titration)
- Test cost: 25(OH)D typically $25–75 cash-pay; often covered if risk factors documented
- K2 reminder: If D3 dose ≥2,000 IU/d ongoing, pair with Vitamin K2 MK-7 100–200 mcg/d
What We Don't Know
- Optimal 25(OH)D target for non-bone outcomes (20 vs 30 vs 40 vs 50 ng/mL)
- Long-term safety at 25(OH)D consistently >80 ng/mL
- Whether VDR / CYP2R1 genotyping should drive dosing in non-responders
- Whether telomere + epigenetic-aging signal translates to hard clinical outcomes
- Whether correcting D3 deficiency in cancer patients improves survival (trials ongoing)
- Individual variance in dose-response (some need 5,000 IU/d to reach 30 ng/mL)
- Mechanism of paradoxical reactions (anxiety, fatigue worsening, palpitations) in subset of users
- Whether bolus dosing is inherently inferior or just poorly executed in trials
- Whether Coimbra-level doses are genuinely required for autoimmune "D resistance" or placebo + survivorship
- How D3 interacts with checkpoint-inhibitor immunotherapy (early Science 2024 signal needs translation)
References
Landmark Trials & Meta-Analyses (pre-2024)
- Manson JE et al. (2019). VITAL trial — D3 2,000 IU/d vs placebo, N=25,871. Null for cancer/CVD incidence. NEJM. PMID 30415629
- Manson JE et al. (2019). VITAL CVD arm — null MI/stroke. NEJM. PMID 30415628
- Hahn J et al. (2022). VITAL autoimmune disease — HR 0.78. BMJ. PMID 34756744
- Martineau AR et al. (2017). IPD meta-analysis — D3 ↓ respiratory infections 12% overall, 42% in deficient. BMJ. PMID 28202713
- Bischoff-Ferrari HA et al. (2012). Pooled analysis — D3 ≥800 IU/d ↓ hip fractures 30%. NEJM. PMID 22762317
- Bolland MJ et al. (2018). Meta-analysis — D3 alone no benefit for fractures/falls/BMD in unselected adults. Lancet D&E. PMID 30293909
- Zhao JG et al. (2017). D3 alone no fracture ↓; D3+Ca ↓ hip fracture 16%. JAMA. PMID 29279934
- Avenell A et al. (2014). Cochrane — D3+Ca ↓ hip fracture 16%, total fracture 5%. N=91,791. PMID 24729336
- Bischoff-Ferrari HA et al. (2004). Falls meta — 22% reduction. JAMA. PMID 15886381
- Pittas AG et al. (2019). D2d trial — 4,000 IU/d did not prevent T2D (HR 0.88, NS). NEJM. PMID 31132708
- Pittas AG et al. (2023). D2d intratrial subgroup — 25(OH)D ≥100 nmol/L → 76% risk reduction. PMID 37001590
- Hollis BW et al. (2017). Maternal D3 ↓ preterm birth 27%. PMID 29217750
- Raffield LM et al. (2019). IBD D3 4,000 IU — ↑ levels, no activity ↓. PMID 31533487
- Scragg R (2019). Threshold effect — benefits at <20 ng/mL. PMID 30841596
- Autier P et al. (2014). D3 does not prevent most chronic diseases in gen pop. Lancet D&E. PMID 24622671
- Bjelakovic G et al. (rickets review). PMID 34969941
- Ford JA et al. (2014). Antenatal pregnancy outcomes. PMID 31860103
- Pittas AG et al. (2019). D2d T2D. PMID 31173679
- Urashima M et al. (blood pressure + deficient). PMID 37895163
- COVID-19 mortality meta. PMID 41156485
2024–2026 Evidence Updates
- Demay MB et al. (2024). NEW Endocrine Society guideline — dropped targets + screening for healthy <75. JCEM. PMID 38828931
- Demay MB et al. (2024). ES guideline systematic review. PMID 38828942
- Jolliffe DA et al. (2025). Updated respiratory infection stratified meta — attenuated signal. Lancet D&E. PMID 39993397
- Hahn J et al. (2024). VITAL autoimmune follow-up — HR persists 2 yr. Arthritis Rheumatol. PMID 38272846
- Zaidi A et al. (2025). VITAL telomere sub-study — 140 bp reduced attrition. Am J Clin Nutr. PMID 40409468
- Ballegooijen AJ et al. (2025). India telomere replication in prediabetic women. PMID 40862088
- Kuznia S et al. (2023). IPD meta-analysis — cancer mortality HR 0.88 daily dosing. PMID 37004841
- Ruiz-García A et al. (2023). 80-RCT mortality meta — no all-cause mortality overall. PMID 37111028
- Waterhouse M et al. (2025). D-Health cancer incidence — null. PMID 40096917
- Thompson B et al. (2026). D-Health cardiometabolic — null. PMID 41599971
- Neale RE et al. (2022). D-Health all-cause mortality — null. PMID 35026158
- LeBoff MS et al. (2022). VITAL fractures — null in midlife/older. PMID 35939577
- Dawson-Hughes B et al. (2022). DO-HEALTH falls — null. PMID 35136915
- Bischoff-Ferrari HA et al. (2024). DO-HEALTH bone. PMID 38613445
- Bischoff-Ferrari HA et al. (2025). DO-HEALTH DNA methylation — reduced epigenetic aging. PMID 39900648
- Bischoff-Ferrari HA et al. (2025). DO-HEALTH vertebral fracture — null. PMID 40492704
- Bischoff-Ferrari HA et al. (2025). DO-HEALTH sarcopenia. PMID 39565152
- Bischoff-Ferrari HA et al. (2024). DO-HEALTH CVD. PMID 38199870
- Bischoff-Ferrari HA et al. (2025). DO-HEALTH sclerostin. PMID 39657964
- Virtanen JK et al. (2025). Finnish Vitamin D Trial dementia — null. PMID 40243375
- Okereke OI et al. (2022). D-Health depression — null. PMID 36462182
- Nguyen T et al. (2026). DepFuD depression RCT — null. PMID 41933624
- Smith K et al. (2026). Finnish depression incidence RCT — null. PMID 41506003
- Chen L et al. (2026). Depression dose-response meta — modest at >50 µg/d. PMID 41923913
- Ganmaa D et al. (2026). Mongolia COVID-19 + Long COVID RCT — null. PMID 41826107
- Kow CS et al. (2024). COVID-19 ICU mortality meta. PMID 39225947
- Palacios C et al. (2024). Cochrane pregnancy. PMID 39077939
- Mullin GE et al. (2024). Preeclampsia meta. PMID 39716171
- Li N et al. (2026). GDM meta — improves glucose. PMID 41737411
- Harvey NC et al. (2026). MAVIDOS offspring bone 6-yr. PMID 41802552
- Zhao Y et al. (2026). PCOS-IVF BMJ multicentre RCT — null live birth. PMID 41702641
- Wang F et al. (2026). Autoimmune inflammation meta. PMID 41952022
- Paul AK et al. (2026). MS relapse meta. PMID 41983136
- Matthews DR et al. (2026). Prostate ProsD Phase II — null. PMID 41423505
- Song M et al. (2026). Colorectal + inflammation RCT. PMID 41507560
- Liu X et al. (2026). Elderly body composition alone — null. PMID 41319491
- Park S et al. (2026). Sarcopenia network meta — adjunct positive. PMID 41422832
- Hollis BW et al. (2026). Maternal D → child health review. PMID 39834161
- Amrein K et al. (2026). T2D prevention mini-review. PMID 41707752
- Kodama Y et al. (2026). Post-COVID ME/CFS Japan RCT. PMID 41683343
- Zhou Z et al. (2026). Cognition/MCI network meta — null. PMID 41764841
- Lee H et al. (2025). Sleep quality meta — modest positive. PMID 41470897
- Hupin D et al. (2025). EVIDIMS MS neuroprotection. PMID 40554210
- Karim F et al. (2025). ViDiSAM Pakistan pediatric malnutrition RCT. PMID 40089464
- Arpadi SM et al. (2026). HIV adolescents BMD RCT. PMID 41391456
- Petrovic M et al. (2025). Psoriasis network meta. PMID 41459063
- Garcia M et al. (2026). COPD deficient RCT. PMID 41914100
- Song Y et al. (2026). MAFLD meta. PMID 41478593
- Dyer SM et al. (2025). Cochrane falls in care facilities — null alone. PMID 40832852
- Williamson PR et al. (2024). Cochrane COPD. PMID 39329240
- Chakhtoura M et al. (2024). Cochrane bariatric. PMID 39351881
- Tao S et al. (2024). Intermittent/bolus vs daily meta — bolus inferior. PMID 38615341
- Mortality umbrella update (2024). PMID 39178988
- All-cause mortality meta 2026. PMID 41719624
Dosing, Formulations, Pharmacokinetics
- Holick MF et al. (2011). Prior Endocrine Society guideline — target 30–50 ng/mL. PMID 21646368 (superseded)
- Pludowski P et al. (2018). Expert consensus — target 30–50 ng/mL. PMID 28216084
- Pludowski P, Grant WB et al. (2025). Counter-argument to 2024 ES guideline. PMID 39861407
- Holick MF (2024). Critique of 2024 ES guideline. PMID 39486479
- Cashman KD et al. (2017). IPD meta-regression — 1,000–1,500 IU/d → 30 ng/mL in 97.5%. PMID 28480855
- Tripkovic L et al. (2012). D3 raises 25(OH)D 87% more than D2. PMID 22552031
- van den Heuvel EGHM et al. (2024). D3 vs D2 BMI-modified meta. PMID 37865222
- Bouden I et al. (2025). Calcifediol vs cholecalciferol meta — calcifediol ~3× more potent. PMID 39385006
- Turck D et al. (EFSA, 2023). Tolerable Upper Intake Level 100 µg/d adults. PMID 37560437
- Turck D et al. (EFSA, 2024). Calcidiol conversion factor. PMID 38273990
- Krist AH et al. (USPSTF, 2021). Insufficient evidence for screening — "I" statement. PMID 33847711
- USPSTF evidence report 2021. PMID 33847712
- USPSTF companion (2021). PMID 33900706
Safety & Toxicity
- Galior K et al. (2018). Toxicity case review — most cases >40,000 IU/d for months. PMID 30042329
- Marcinowska-Suchowierska E et al. (2018). Toxicity at 25(OH)D >150 ng/mL. PMID 30294301
- Dudenkov DV et al. (2015). Toxicity (>100 ng/mL) 0.02% despite 20-fold ↑ in high levels. PMID 25939935
- Vasil K et al. (2026). "How Much Is Too Much?" review — UL 4,000 IU/d conservative. PMID 41219595
- Moon RJ et al. (2024). Mayo Clin Proc — questions 2024 ES guideline went too far. PMID 39938796
- Jafari T et al. (2026). Paraneoplastic hypercalcemia in dedifferentiated liposarcoma. PMID 41980790
- Lee DW et al. (2026). Rodenticide cholecalciferol toxicity case. PMID 41992351
Pharmacogenomics
- Misra R et al. (2026). VDR + Graves' disease. PMID 41989523
- Maeda SS et al. (2026). VDR + lupus. PMID 41693069
- Park JH et al. (2026). VDR + CRC prognosis. PMID 41987077
- Khan M et al. (2026). VDR + T2D metabolic control. PMID 40292491
- Nguyen PT et al. (2026). VDR + dengue severity. PMID 41978759
- Chowdhury S et al. (2026). VDR + leprosy trophic ulcers. PMID 41961906
- Torres J et al. (2026). VDBP muscle atrophy mechanism. PMID 41963327
Additional Resources
- NIH Vitamin D Fact Sheet: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- ClinicalTrials.gov: 2,573 registered D3 trials (1,683 completed, 130 recruiting) as of 2026-04-17